Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.
Clin Endocrinol (Oxf)Jun 1, 2026 (epub)
John Newell-Price, Beverly M K Biller, Maria Fleseriu et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled analysis of the Phase III LINC 3 and LINC 4 trials evaluated the impact of osilodrostat on health-related quality of life (HRQoL) in 185 patients with Cushing's disease. Results showed significant improvements in CushingQoL scores, with a mean increase of +15.32 by Week 72, indicating clinically meaningful enhancements in patient-reported outcomes.
Key findings
- CushingQoL score improved by +7.72 at Week 12 and +15.32 at Week 72 (all p < 0.001).
- BDI-II score decreased by -19.0% at Week 12 and -41.2% at Week 72 (all p < 0.001).
- EQ-5D-5L utility score improved significantly over Weeks 26-72 (p < 0.01).
- Improvements in HRQoL were consistent across all patient subgroups based on hypercortisolism severity.
Why it matters
Improvements in health-related quality of life are crucial for patients with Cushing's disease, as they reflect the effectiveness of treatment in alleviating symptoms and enhancing overall well-being. Understanding these outcomes can guide clinicians in managing patient care and expectations.